mavenclad (cladribine) 10mg tablet

Mavenclad (cladribine) 10mg tablets are an oral medication prescribed primarily for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is intended for patients who have tried other treatments without sufficient success or who have difficulty with injectable therapies. Mavenclad is unique in its use of selective immune reconstitution therapy (SIRT), which targets specific immune cells thought to play a role in MS.

How Mavenclad Works

Cladribine, the active ingredient in Mavenclad, is a purine analog that selectively targets and reduces specific white blood cells, namely lymphocytes (B and T cells), which are part of the immune system. In multiple sclerosis, the immune system attacks the protective myelin sheath surrounding nerve cells. By targeting and reducing certain lymphocytes, Mavenclad helps to suppress the immune system’s attack on the nervous system. The therapy is designed to be taken in two annual treatment courses, each lasting a few days, with no further dosing needed between the treatment cycles. This approach offers patients long-lasting results with a relatively low treatment burden.

Indications

Mavenclad is approved for use in the following cases:

• Relapsing-Remitting Multiple Sclerosis (RRMS): Used to reduce the frequency of relapses in adults with RRMS.
• Active Secondary Progressive Multiple Sclerosis (SPMS): Helps slow disease progression in SPMS with relapses.

Side Effects

Common side effects of Mavenclad include:

• Headache
• Cold-like symptoms (e.g., sore throat, congestion)
• Lowered lymphocyte counts
• Rash or skin irritation
• Nausea

Serious side effects can include:

• Increased risk of infections (e.g., herpes zoster)
• Liver function abnormalities
• Bone marrow suppression
• Risk of developing malignancies

Contraindications

Mavenclad should not be used in the following cases:

• Pregnancy: Contraindicated due to risk of fetal harm.
• Active Infection: Not for use in individuals with active chronic infections.
• Cancer: Contraindicated in patients with current or recent history of malignancy.
• HIV Infection: Not for use in patients with HIV due to immunosuppressive effects.
• Allergy to Cladribine: Not for use in patients with known hypersensitivity to cladribine.

Price of Mavenclad in Different Countries

The table below provides approximate pricing for Mavenclad (cladribine) 10mg tablets in various countries. Prices may vary depending on the pharmacy, insurance coverage, and local regulations.

Country	Price (per tablet)	Source
United States	$200 – $250	GoodRx
Canada	CAD 230 – CAD 280	PharmacyChecker
United Kingdom	£180 – £220	NHS UK
Australia	AUD 300 – AUD 350	PBS Australia
India	INR 15,000 – INR 18,000	1mg India

Top 5 Global Brands for Cladribine-based MS Therapy

• Mavenclad (EMD Serono) – A widely available brand for treating relapsing MS.
• Cladopa (Bavarian Nordic) – Known for cladribine therapy for specific MS cases.
• Cladribine Tablets (Various generics) – Several manufacturers produce cladribine tablets, primarily for MS treatments.
• Cladrix (Regen Biopharma) – Another cladribine-based option aimed at immune modulation.
• NODAX (Teva Pharmaceuticals) – Known in some regions as a cladribine-based therapy for MS patients.